List view / Grid view
20 April 2015 | By Victoria White
Mymetics is leading a consortium to development thermo stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates.
17 April 2015 | By Victoria White
Novogen and the Feinstein Institute for Medical Research are to collaborate to develop effective treatments for brain cancers...
17 April 2015 | By Victoria White
Takeda and CiRA to work together to develop clinical applications of induced pluripotent stem cells in areas such as diabetes mellitus and immunotherapy...
15 April 2015 | By Victoria White
Celprogen have developed a novel pharmacological Inhibitor, CEP1430, that is capable of inhibiting the growth of the human pancreatic cancer tumour...
15 April 2015 | By Victoria White
Lexicon and Bristol-Myers Squibb have selected a development candidate for neuropathic pain as part of their drug discovery and development alliance...
13 April 2015 | By Victoria White
Medivir and CRT have announced a partnership to develop a new class of drugs that has shown promise for treating a range of different cancers...
13 April 2015 | By Victoria White
Bayer HealthCare has expanded its collaboration with the Broad Institute to include cardiovascular genomics and drug discovery...
13 April 2015 | By Victoria White
Eisai and Genomics are to collaborate to use Genomics' statistical analyses of large-scale multi-phenotype data to inform Eisai's drug discovery process...
9 April 2015 | By Victoria White
Novogen has announced that studies conducted at UQDI revealed that experimental drug Anisina killed melanoma cells irrespective of their mutational status...
9 April 2015 | By Caroline Richards, Editor, Drug Target Review
In this NGS In-Depth Focus; How next-generation sequencing came to be, plus a brief history & Data management for large-scale NGS-based research projects...
Tim Hammonds from Cancer Research Technology Discoveries explains how academic HTS laboratories came into being and outlines the challenges facing the new HTS model...
Wolfgang Fecke and Christine Williams from UCB discuss the industry’s approach to drug discovery with costs escalating and output failing to achieve the corresponding increases in revenue...
In his fascinating overview of label-free analysis, Dr. Masson introduces the four main label-free methods: physical, electrochemical, mass-based and optical techniques, before providing the reader with in-depth insight into the most common label-free technique within the pharmaceutical industry: surface plasmon resonance (SPR)...
This article evaluates a GADD45a-GFP human cell assay for rapid and reliable in vitro early genotoxicity screening...
Preview of the upcoming foreword in our April issue, written by Sheraz Gul, Vice President and Head of Biology at Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Hamburg, Germany...
